Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Modalis Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
JCR, Modalis Advance Joint Research for Novel Gene Therapy Development
Details : Under the terms of the agreement, both companies will collaborate to conduct preclinical studies aimed at developing a novel gene therapy for CNS diseases.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 05, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Modalis Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ASP3652,ABX-003
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Autobahn Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Autobahn has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug c...
Product Name : ASP3652
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 05, 2021
Lead Product(s) : ASP3652,ABX-003
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Autobahn Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : QP50ESO5RA
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : $380.0 million
Deal Type : Collaboration
Details : Biohaven will get exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. The portfolio includes the lead ...
Product Name : HTL0022562
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
January 12, 2020
Lead Product(s) : QP50ESO5RA
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : $380.0 million
Deal Type : Collaboration